EU: Pivotal Moment For Roche’s Faster-To-Apply Breast Cancer Combo
Patients preferred subcutaneous injection compared to standard intravenous administration
The European Medicines Agency is this week deciding whether or not to recommend pan-EU marketing approval for Roche’s subcutaneously injected fixed-dose combination of Perjeta and Herceptin. The agency is also deciding on a marketing application for the company's flu antiviral, baloxavir marboxil.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.
While the European Medicines Agency and industry speculate as to why 2022 saw far fewer applications for a place on the priority medicines scheme for drugs for unmet medical needs, they are enthusiastic about improvements to the initiative that are set to be trialed soon.
PTC Therapeutics has managed to convince England’s health technology assessment institute to reverse its recommendation against routine commissioning for Translarna.